Filamentous hemagglutinin of Bordetella pertussis: A key adhesin with immunomodulatory properties?

Future Microbiology

Volumn 9, Issue 12, 2014, Pages 1339-1360

  Romero, Rodrigo Villarino ^a   Osicka, Radim ^a   Sebo, Peter ^a  

^a INSTITUTE OF MICROBIOLOGY   (Czech Republic)

Author keywords

adhesion; Bordetella; filamentous hemagglutinin; immunomudulation; integrins; pertussis; vaccine; virulence factors

Indexed keywords

ADHESIN; HEMAGGLUTININ; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 12; OUTER MEMBRANE PROTEIN; PERTUSSIS TOXIN; PERTUSSIS VACCINE; SPACER DNA; TRANSFORMING GROWTH FACTOR BETA; VERY LATE ACTIVATION ANTIGEN 5; VIRULENCE FACTOR; BORDETELLA VIRULENCE FACTOR; CD47 ANTIGEN; CD47 PROTEIN, HUMAN; DIPHTHERIA PERTUSSIS TETANUS VACCINE; FILAMENTOUS HEMAGGLUTININ ADHESIN, BORDETELLA PERTUSSIS; IMMUNOLOGIC FACTOR;

ANTIINFLAMMATORY ACTIVITY; BACTERIAL GENE; BACTERIUM ADHERENCE; BINDING AFFINITY; BIOGENESIS; BORDETELLA BRONCHISEPTICA; BORDETELLA PERTUSSIS; CELL MIGRATION; COLITIS; GENE LOCUS; HUMAN; IMMUNOMODULATION; NEUTROPHIL; NONHUMAN; OPERON; PERTUSSIS; PHAGOCYTE; PHAGOCYTOSIS; PSEUDOGENE; REGULATORY T LYMPHOCYTE; RESPIRATORY TRACT INFECTION; RESPIRATORY TRACT MUCOSA; REVIEW; STRUCTURAL GENE; STRUCTURE ACTIVITY RELATION; TH1 CELL; TH17 CELL; ANIMAL; CHEMISTRY; GENETICS; IMMUNOLOGY; METABOLISM; MICROBIOLOGY; PATHOGENICITY; WHOOPING COUGH;

BACTERIA (MICROORGANISMS); BORDETELLA; BORDETELLA PERTUSSIS;

ADHESINS, BACTERIAL; ANIMALS; ANTIGENS, CD47; BORDETELLA PERTUSSIS; DIPHTHERIA-TETANUS-ACELLULAR PERTUSSIS VACCINES; HUMANS; IMMUNOLOGIC FACTORS; VIRULENCE FACTORS, BORDETELLA; WHOOPING COUGH;

EID: 84919832388     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.14.77     Document Type: Review

References (160)

1. Mattoo S, Cherry JD. Molecular pathogenesis, epidemiology, and clinical manifestations of respiratory infections due to Bordetella pertussis and other Bordetella subspecies. Clin. Microbiol. Rev. 18(2), 326-382 (2005).
2. Hodder SL, Cherry JD, Mortimer EA Jr, Ford AB, Gornbein J, Papp K. Antibody responses to Bordetella pertussis antigens and clinical correlations in elderly community residents. Clin. Infect. Dis. 31(1), 7-14 (2000).
3. Cherry JD. The role of Bordetella pertussis infections in adults in the epidemiology of pertussis. Dev. Biol. Stand. 89, 181-186 (1997).
4. Cherry JD. Pertussis in the preantibiotic and prevaccine era, with emphasis on adult pertussis. Clin. Infect. Dis. 28(Suppl. 2), S107-S111 (1999).
5. Cherry JD. Epidemiology of pertussis. Pediatr. Infect. Dis. J. 25(4), 361-362 (2006).
6. Pittman M. History of the development of pertussis vaccine. Dev. Biol. Stand. 73, 13-29 (1991).
7. Sato Y, Sato H. Development of acellular pertussis vaccines. Biologicals 27(2), 61-69 (1999).
8. Crowcroft NS, Stein C, Duclos P, Birmingham M. How best to estimate the global burden of pertussis? Lancet Infect. Dis. 3(7), 413-418 (2003).
9. Cherry JD. The present and future control of pertussis. Clin. Infect. Dis. 51(6), 663-667 (2010).
10. Cherry JD. Pertussis: challenges today and for the future. PLoS Pathog. 9(7), e1003418 (2013).
11. Baraff LJ, Manclark CR, Cherry JD, Christenson P, Marcy SM. Analyses of adverse reactions to diphtheria and tetanus toxoids and pertussis vaccine by vaccine lot, endotoxin content, pertussis vaccine potency and percentage of mouse weight gain. Pediatr. Infect. Dis. J. 8(8), 502-507 (1989).
12. Misegades LK, Winter K, Harriman K et al. Association of childhood pertussis with receipt of 5 doses of pertussis vaccine by time since last vaccine dose, California, 2010. JAMA 308(20), 2126-2132 (2012).
13. Tartof SY, Lewis M, Kenyon C et al. Waning immunity to pertussis following 5 doses of DTaP. Pediatrics 131(4), e1047-e1052 (2013).
14. Witt MA, Arias L, Katz PH, Truong ET, Witt DJ. Reduced risk of pertussis among persons ever vaccinated with whole cell pertussis vaccine compared with recipients of acellular pertussis vaccines in a large US cohort. Clin. Infect. Dis. 56(9), 1248-1254 (2013).
15. Witt MA, Katz PH, Witt DJ. Unexpectedly limited durability of immunity following acellular pertussis vaccination in preadolescents in a North American outbreak. Clin. Infect. Dis. 54(12), 1730-1735 (2012).
16. Cherry JD. Why do pertussis vaccines fail? Pediatrics 129(5), 968-970 (2012).
17. Cherry JD, Olin P. The science and fiction of pertussis vaccines. Pediatrics 104(6), 1381-1383 (1999).
18. Warfel JM, Zimmerman LI, Merkel TJ. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proc. Natl Acad. Sci. USA 111(2), 787-792 (2014).
19. Australian Government Department of Health, National Notifiable Diseases Surveillance System: number of notifications of Pertussis in Australia in the period of 1991 to 2014. www9.health.gov.au/cda/source/rpt-3.cfm
20. Reported pertussis cases to the National Notifiable Disease Surveillance System of CDC of the USA from 1922 to 2013. www.cdc.gov/pertussis/images/incidence
21. Octavia S, Sintchenko V, Gilbert GL et al. Newly emerging clones of Bordetella pertussis carrying prn2 and ptxP3 alleles implicated in Australian pertussis epidemic in 2008-2010. J. Infect. Dis. 205(8), 1220-1224 (2012).
22. Winter K, Harriman K, Zipprich J et al. California pertussis epidemic, 2010. J. Pediatr. 161(6), 1091-1096 (2012).
23. Melvin JA, Scheller EV, Miller JF, Cotter PA. Bordetella pertussis pathogenesis: current and future challenges. Nature Rev. Microbiol. 12(4), 274-288 (2014).
24. Shrivastava R, Miller JF. Virulence factor secretion and translocation by Bordetella species. Curr. Opin. Microbiol. 12(1), 88-93 (2009).
25. Carbonetti NH. Pertussis toxin and adenylate cyclase toxin: key virulence factors of Bordetella pertussis and cell biology tools. Future Microbiol. 5(3), 455-469 (2010).
26. Locht C, Coutte L, Mielcarek N. The ins and outs of pertussis toxin. FEBS J. 278(23), 4668-4682 (2011).
27. Vojtova J, Kamanova J, Sebo P. Bordetella adenylate cyclase toxin: a swift saboteur of host defense. Curr. Opin. Microbiol. 9(1), 69-75 (2006).
28. Fennelly NK, Sisti F, Higgins SC et al. Bordetella pertussis expresses a functional type III secretion system that subverts protective innate and adaptive immune responses. Infect. Immun. 76(3), 1257-1266 (2008).
29. Gaillard ME, Bottero D, Castuma CE, Basile LA, Hozbor D. Laboratory adaptation of Bordetella pertussis is associated with the loss of type three secretion system functionality. Infect. Immun. 79(9), 3677-3682 (2011).
30. Han Hj, Kuwae A, Abe A, Arakawa Y, Kamachi K. Differential expression of type III effector BteA protein due to IS481 insertion in Bordetella pertussis. PLoS ONE 6(3), e17797 (2011).
31. Hegerle N, Rayat L, Dore G, Zidane N, Bedouelle H, Guiso N. In-vitro and in-vivo analysis of the production of the Bordetella type three secretion system effector A in Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica. Microbes Infect. 15(5), 399-408 (2013).
32. Villarino Romero R, Bibova I, Cerny O et al. The Bordetella pertussis type III secretion system tip complex protein Bsp22 is not a protective antigen and fails to elicit serum antibody responses during infection of humans and mice. Infect. Immun. 81(8), 2761-2767 (2013).
33. Marr N, Shah NR, Lee R, Kim EJ, Fernandez RC. Bordetella pertussis autotransporter Vag8 binds human C1 esterase inhibitor and confers serum resistance. PLoS ONE 6(6), e20585 (2011).
34. Everest P, Li J, Douce G et al. Role of the Bordetella pertussis P.69/pertactin protein and the P.69/pertactin RGD motif in the adherence to and invasion of mammalian cells. Microbiology 142(Pt 11), 3261-3268 (1996).
35. Geuijen CA, Willems RJ, Bongaerts M, Top J, Gielen H, Mooi FR. Role of the Bordetella pertussis minor fimbrial subunit, FimD, in colonization of the mouse respiratory tract. Infect. Immun. 65(10), 4222-4228 (1997).
36. Geuijen CA, Willems RJ, Mooi FR. The major fimbrial subunit of Bordetella pertussis binds to sulfated sugars. Infect. Immun. 64(7), 2657-2665 (1996).
37. Hannah JH, Menozzi FD, Renauld G, Locht C, Brennan Mj. Sulfated glycoconjugate receptors for the Bordetella pertussis adhesin filamentous hemagglutinin (FHA) and mapping of the heparin-binding domain on FHA. Infect. Immun. 62(11), 5010-5019 (1994).
38. Hazenbos WL, Geuijen CA, Van Den Berg BM, Mooi FR, Van Furth R. Bordetella pertussis fimbriae bind to human monocytes via the minor fimbrial subunit FimD. J. Infect. Dis. 171(4), 924-929 (1995).
39. Hazenbos WL, Van Den Berg BM, Van't Wout JW, Mooi FR, Van Furth R. Virulence factors determine attachment and ingestion of nonopsonized and opsonized Bordetella pertussis by human monocytes. Infect. Immun. 62(11), 4818-4824 (1994).
40. Charles IG, Dougan G, Pickard D et al. Molecular cloning and characterization of protective outer membrane protein P.69 from Bordetella pertussis. Proc. Natl Acad. Sci. USA 86(10), 3554-3558 (1989).
41. Ishibashi Y, Claus S, Relman DA. Bordetella pertussis filamentous hemagglutinin interacts with a leukocyte signal transduction complex and stimulates bacterial adherence to monocyte CR3 (CD11b/CD18). J. Exp. Med. 180(4), 1225-1233 (1994).
42. Ishibashi Y, Relman DA, Nishikawa A. Invasion of human respiratory epithelial cells by Bordetella pertussis: possible role for a filamentous hemagglutinin Arg-Gly-Asp sequence and alpha5beta1 integrin. Microb. Pathog. 30(5), 279-288 (2001).
43. Julio SM, Inatsuka CS, Mazar J, Dieterich C, Relman DA, Cotter PA. Natural-host animal models indicate functional interchangeability between the filamentous haemagglutinins of Bordetella pertussis and Bordetella bronchiseptica and reveal a role for the mature C-terminal domain, but not the RGD motif, during infection. Mol. Microbiol. 71(6), 1574-1590 (2009).
44. Leininger E, Ewanowich CA, Bhargava A, Peppler MS, Kenimer JG, Brennan MJ. Comparative roles of the Arg-Gly-Asp sequence present in the Bordetella pertussis adhesins pertactin and filamentous hemagglutinin. Infect. Immun. 60(6), 2380-2385 (1992).
45. Mazar J, Cotter PA. Topology and maturation of filamentous haemagglutinin suggest a new model for two-partner secretion. Mol. Microbiol. 62(3), 641-654 (2006).
46. Prasad SM, Yin Y, Rodzinski E, Tuomanen EI, Masure HR. Identification of a carbohydrate recognition domain in filamentous hemagglutinin from Bordetella pertussis. Infect. Immun. 61(7), 2780-2785 (1993).
47. Scarlato V, Arico B, Prugnola A, Rappuoli R. Sequential activation and environmental regulation of virulence genes in Bordetella pertussis. EMBO J. 10(12), 3971-3975 (1991).
48. Hafler JP, Pohl-Koppe A. The cellular immune response to Bordetella pertussis in two children with whooping cough. Eur. J. Med Res. 3(11), 523-526 (1998).
49. Cherry JD, Gornbein J, Heininger U, Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 16(20), 1901-1906 (1998).
50. Mascart F, Verscheure V, Malfroot A et al. Bordetella pertussis infection in 2-month-old infants promotes type 1 T cell responses. J. Immunol. 170(3), 1504-1509 (2003).
51. Mills KH. Immunity to Bordetella pertussis. Microbes Infect. 3(8), 655-677 (2001).
52. Novotny P, Chubb AP, Cownley K, Charles IG. Biologic and protective properties of the 69-kDa outer membrane protein of Bordetella pertussis: a novel formulation for an acellular pertussis vaccine. J. Infect. Dis. 164(1), 114-122 (1991).
53. Olin P, Rasmussen F, Gustafsson L, Hallander HO, Heijbel H. Randomised controlled trial of two-component, threecomponent, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet 350(9091), 1569-1577 (1997).
54. Ryan M, Murphy G, Gothefors L, Nilsson L, Storsaeter J, Mills KH. Bordetella pertussis respiratory infection in children is associated with preferential activation of type 1 T helper cells. J. Infect. Dis. 175(5), 1246-1250 (1997).
55. Storsaeter J, Hallander HO, Gustafsson L, Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 16(20), 1907-1916 (1998).
56. Locht C, Bertin P, Menozzi FD, Renauld G. The filamentous haemagglutinin, a multifaceted adhesion produced by virulent Bordetella spp. Mol. Microbiol. 9(4), 653-660 (1993).
57. Weiss AA, Hewlett EL. Virulence factors of Bordetella pertussis. Annu. Rev. Microbiol. 40, 661-686 (1986).
58. Abramson T, Kedem H, Relman DA. Proinflammatory and proapoptotic activities associated with Bordetella pertussis filamentous hemagglutinin. Infect. Immun. 69(4), 2650-2658 (2001).
59. Abramson T, Kedem H, Relman DA. Modulation of the NF-kappaB pathway by Bordetella pertussis filamentous hemagglutinin. PLoS ONE 3(11), e3825 (2008).
60. Braat H, Mcguirk P, Ten Kate FJ et al. Prevention of experimental colitis by parenteral administration of a pathogenderived immunomodulatory molecule. Gut 56(3), 351-357 (2007).
61. Dieterich C, Relman DA. Modulation of the host interferon response and ISGylation pathway by B. pertussis filamentous hemagglutinin. PLoS ONE 6(11), e27535 (2011).
62. Henderson MW, Inatsuka CS, Sheets AJ et al. Contribution of Bordetella filamentous hemagglutinin and adenylate cyclase toxin to suppression and evasion of interleukin-17-mediated inflammation. Infect. Immun. 80(6), 2061-2075 (2012).
63. Mcguirk P, McCann C, Mills KH. Pathogenspecific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: a novel strategy for evasion of protective T helper type 1 responses by Bordetella pertussis. J. Exp. Med. 195(2), 221-231 (2002).
64. Mcguirk P, Mills KH. Direct antiinflammatory effect of a bacterial virulence factor: IL-10-dependent suppression of IL-12 production by filamentous hemagglutinin from Bordetella pertussis. Eur. J. Immunol. 30(2), 415-422 (2000).
65. Ohman L, Willen R, Hultgren OH, Hultgren Hornquist E. Acellular Bordetella pertussis vaccine enhances mucosal interleukin-10 production, induces apoptosis of activated Th1 cells and attenuates colitis in Galphai2-deficient mice. Clin. Exp. Immunol. 141(1), 37-46 (2005).
66. Munoz JJ, Arai H, Cole RL. Mouseprotecting and histamine-sensitizing activities of pertussigen and fimbrial hemagglutinin from Bordetella pertussis. Infect. Immun. 32(1), 243-250 (1981).
67. Olin P, Hallander HO, Gustafsson L, Reizenstein E, Storsaeter J. How to make sense of pertussis immunogenicity data. Clin. Infect. Dis. 33(Suppl. 4), S288-S291 (2001).
68. Watanabe M, Nakase Y. Mutant of Bordetella pertussis which lacks ability to produce filamentous hemagglutinin. Infect. Immun. 35(3), 1018-1023 (1982).
69. Locht C, Geoffroy MC, Renauld G. Common accessory genes for the Bordetella pertussis filamentous hemagglutinin and fimbriae share sequence similarities with the papC and papD gene families. EMBO J. 11(9), 3175-3183 (1992).
70. Willems RJ, Geuijen C, Van Der Heide HG et al. Mutational analysis of the Bordetella pertussis fim/fha gene cluster: identification of a gene with sequence similarities to haemolysin accessory genes involved in export of FHA. Mol. Microbiol. 11(2), 337-347 (1994).
71. Willems RJ, Van Der Heide HG, Mooi FR. Characterization of a Bordetella pertussis fimbrial gene cluster which is located directly downstream of the filamentous haemagglutinin gene. Mol. Microbiol. 6(18), 2661-2671 (1992).
72. Willems RJ, Geuijen C, Van Der Heide HG et al. Isolation of a putative fimbrial adhesin from Bordetella pertussis and the identification of its gene. Mol. Microbiol. 9(3), 623-634 (1993).
73. Clantin B, Hodak H, Willery E, Locht C, Jacob-Dubuisson F, Villeret V. The crystal structure of filamentous hemagglutinin secretion domain and its implications for the two-partner secretion pathway. Proc. Natl Acad. Sci. USA 101(16), 6194-6199 (2004).
74. Jacob-Dubuisson F, El-Hamel C, Saint N et al. Channel formation by FhaC, the outer membrane protein involved in the secretion of the Bordetella pertussis filamentous hemagglutinin. J. Biol. Chem. 274(53), 37731-37735 (1999).
75. Jacob-Dubuisson F, Locht C, Antoine R. Two-partner secretion in Gram-negative bacteria: a thrifty, specific pathway for large virulence proteins. Mol. Microbiol. 40(2), 306-313 (2001).
76. Stibitz S. Mutations in the bvgA gene of Bordetella pertussis that differentially affect regulation of virulence determinants. J. Bacteriol. 176(18), 5615-5621 (1994).
77. Stibitz S, Aaronson W, Monack D, Falkow S. Phase variation in Bordetella pertussis by frameshift mutation in a gene for a novel two-component system. Nature 338(6212), 266-269 (1989).
78. Williams CL, Boucher PE, Stibitz S, Cotter PA. BvgA functions as both an activator and a repressor to control Bvg phase expression of bipA in Bordetella pertussis. Mol. Microbiol. 56(1), 175-188 (2005).
79. Veal-Carr WL, Stibitz S. Demonstration of differential virulence gene promoter activation in vivo in Bordetella pertussis using RIVET. Mol. Microbiol. 55(3), 788-798 (2005).
80. Delisse-Gathoye AM, Locht C, Jacob F et al. Cloning, partial sequence, expression, and antigenic analysis of the filamentous hemagglutinin gene of Bordetella pertussis. Infect. Immun. 58(9), 2895-2905 (1990).
81. Domenighini M, Relman D, Capiau C et al. Genetic characterization of Bordetella pertussis filamentous haemagglutinin: a protein processed from an unusually large precursor. Mol. Microbiol. 4(5), 787-800 (1990).
82. Relman DA, Domenighini M, Tuomanen E, Rappuoli R, Falkow S. Filamentous hemagglutinin of Bordetella pertussis: nucleotide sequence and crucial role in adherence. Proc. Natl Acad. Sci. USA 86(8), 2637-2641 (1989).
83. Watanabe H, Kanesaki S, Shukuda Y, Mayahara H. The location of filamentous hemagglutinin and pertussis toxin antigens of Bordetella pertussis by immunoelectron microscopy. J. Electron. Microsc. 38(3), 172-181 (1989).
84. Coutte L, Antoine R, Drobecq H, Locht C, Jacob-Dubuisson F. Subtilisin-like autotransporter serves as maturation protease in a bacterial secretion pathway. EMBO J. 20(18), 5040-5048 (2001).
85. Noel CR, Mazar J, Melvin JA, Sexton JA, Cotter PA. The prodomain of the Bordetella two-partner secretion pathway protein FhaB remains intracellular yet affects the conformation of the mature C-terminal domain. Mol. Microbiol. 86(4), 988-1006 (2012).
86. Jacob-Dubuisson F, Buisine C, Mielcarek N, Clement E, Menozzi FD, Locht C. Aminoterminal maturation of the Bordetella pertussis filamentous haemagglutinin. Mol. Microbiol. 19(1), 65-78 (1996).
87. Clantin B, Delattre As, Rucktooa P et al. Structure of the membrane protein FhaC: a member of the Omp85-TpsB transporter superfamily. Science 317(5840), 957-961 (2007).
88. Chevalier N, Moser M, Koch Hg et al. Membrane targeting of a bacterial virulence factor harbouring an extended signal peptide. J. Mol. Microbiol. Biotechnol. 8(1), 7-18 (2004).
89. Lambert-Buisine C, Willery E, Locht C, Jacob-Dubuisson F. N-terminal characterization of the Bordetella pertussis filamentous haemagglutinin. Mol. Microbiol. 28(6), 1283-1293 (1998).
90. Von Heijne G. A new method for predicting signal sequence cleavage sites. Nucleic Acids Res. 14(11), 4683-4690 (1986).
91. Guedin S, Willery E, Locht C, Jacob-Dubuisson F. Evidence that a globular conformation is not compatible with FhaC-mediated secretion of the Bordetella pertussis filamentous haemagglutinin. Mol. Microbiol. 29(3), 763-774 (1998).
92. Renauld-Mongenie G, Cornette J, Mielcarek N, Menozzi FD, Locht C. Distinct roles of the N-terminal and C-terminal precursor domains in the biogenesis of the Bordetella pertussis filamentous hemagglutinin. J. Bacteriol. 178(4), 1053-1060 (1996).
93. Coutte L, Willery E, Antoine R, Drobecq H, Locht C, Jacob-Dubuisson F. Surface anchoring of bacterial subtilisin important for maturation function. Mol. Microbiol. 49(2), 529-539 (2003).
94. Coutte L, Alonso S, Reveneau N et al. Role of adhesin release for mucosal colonization by a bacterial pathogen. J. Exp. Med. 197(6), 735-742 (2003).
95. Makhov AM, Hannah JH, Brennan Mj et al. Filamentous hemagglutinin of Bordetella pertussis. A bacterial adhesin formed as a 50-nm monomeric rigid rod based on a 19-residue repeat motif rich in beta strands and turns. J. Mol. Biol. 241(1), 110-124 (1994).
96. Kajava AV, Cheng N, Cleaver R et al. Beta-helix model for the filamentous haemagglutinin adhesin of Bordetella pertussis and related bacterial secretory proteins. Mol. Microbiol. 42(2), 279-292 (2001).
97. Hashimoto C, Hudson KL, Anderson KV. The Toll gene of Drosophila, required for dorsal-ventral embryonic polarity, appears to encode a transmembrane protein. Cell 52(2), 269-279 (1988).
98. Kobe B, Deisenhofer J. Crystal structure of porcine ribonuclease inhibitor, a protein with leucine-rich repeats. Nature 366(6457), 751-756 (1993).
99. Lopez JA, Chung DW, Fujikawa K, Hagen FS, Davie EW, Roth GJ. The alpha and beta chains of human platelet glycoprotein Ib are both transmembrane proteins containing a leucine-rich amino acid sequence. Proc. Natl Acad. Sci. USA 85(7), 2135-2139 (1988).
100. Reinke R, Krantz DE, Yen D, Zipursky SL. Chaoptin, a cell surface glycoprotein required for Drosophila photoreceptor cell morphogenesis, contains a repeat motif found in yeast and human. Cell 52(2), 291-301 (1988).
101. Kimura A, Mountzouros KT, Relman DA, Falkow S, Cowell JL. Bordetella pertussis filamentous hemagglutinin: evaluation as a protective antigen and colonization factor in a mouse respiratory infection model. Infect. Immun. 58(1), 7-16 (1990).
102. Redhead K. An assay of Bordetella pertussis adhesion to tissue-culture cells. J. Med. Microbiol. 19(1), 99-108 (1985).
103. Sato Y, Izumiya K, Sato H, Cowell JL, Manclark CR. Role of antibody to leukocytosis-promoting factor hemagglutinin and to filamentous hemagglutinin in immunity to pertussis. Infect. Immun. 31(3), 1223-1231 (1981).
104. Tuomanen E, Towbin H, Rosenfelder G et al. Receptor analogs and monoclonal antibodies that inhibit adherence of Bordetella pertussis to human ciliated respiratory epithelial cells. J. Exp. Med. 168(1), 267-277 (1988).
105. Tuomanen E, Weiss A. Characterization of two adhesins of Bordetella pertussis for human ciliated respiratory-epithelial cells. J. Infect. Dis. 152(1), 118-125 (1985).
106. Tuomanen E, Weiss A, Rich R, Zak F, Zak O. Filamentous hemagglutinin and pertussis toxin promote adherence of Bordetella pertussis to cilia. Dev. Biol. Stand. 61, 197-204 (1985).
107. Urisu A, Cowell JL, Manclark CR. Filamentous hemagglutinin has a major role in mediating adherence of Bordetella pertussis to human WiDr cells. Infect. Immun. 52(3), 695-701 (1986).
108. Gorringe AR, Ashworth LAE, Irons LI, Robinson A. Effect of monoclonal-antibodies on the adherence of Bordetella-pertussis to vero cells. FEMS Microbiol. Lett. 26(1), 5-9 (1985).
109. Relman D, Tuomanen E, Falkow S, Golenbock DT, Saukkonen K, Wright SD. Recognition of a bacterial adhesion by an integrin: macrophage CR3 (alpha M beta 2, CD11b/CD18) binds filamentous hemagglutinin of Bordetella pertussis. Cell 61(7), 1375-1382 (1990).
110. Mobberley-Schuman PS, Weiss AA. Influence of CR3 (CD11b/CD18) expression on phagocytosis of Bordetella pertussis by human neutrophils. Infect. Immun. 73(11), 7317-7323 (2005).
111. Van Den Berg BM, Beekhuizen H, Willems RJ, Mooi FR, Van Furth R. Role of Bordetella pertussis virulence factors in adherence to epithelial cell lines derived from the human respiratory tract. Infect. Immun. 67(3), 1056-1062 (1999).
112. Arico B, Nuti S, Scarlato V, Rappuoli R. Adhesion of Bordetella pertussis to eukaryotic cells requires a time-dependent export and maturation of filamentous hemagglutinin. Proc. Natl Acad. Sci. USA 90(19), 9204-9208 (1993).
113. Zaretzky FR, Gray MC, Hewlett EL. Mechanism of association of adenylate cyclase toxin with the surface of Bordetella pertussis: a role for toxin-filamentous haemagglutinin interaction. Mol. Microbiol. 45(6), 1589-1598 (2002).
114. Perez Vidakovics ML, Lamberti Y, Van Der Pol WL, Yantorno O, Rodriguez ME. Adenylate cyclase influences filamentous haemagglutinin-mediated attachment of Bordetella pertussis to epithelial alveolar cells. FEMS Immunol. Med. Microbiol. 48(1), 140-147 (2006).
115. Bassinet L, Gueirard P, Maitre B, Housset B, Gounon P, Guiso N. Role of adhesins and toxins in invasion of human tracheal epithelial cells by Bordetella pertussis. Infect. Immun. 68(4), 1934-1941 (2000).
116. Ewanowich CA, Melton AR, Weiss AA, Sherburne RK, Peppler MS. Invasion of HeLa 229 cells by virulent Bordetella pertussis. Infect. Immun. 57(9), 2698-2704 (1989).
117. Friedman RL, Nordensson K, Wilson L, Akporiaye ET, Yocum DE. Uptake and intracellular survival of Bordetella pertussis in human macrophages. Infect. Immun. 60(11), 4578-4585 (1992).
118. Saukkonen K, Cabellos C, Burroughs M, Prasad S, Tuomanen E. Integrin-mediated localization of Bordetella pertussis within macrophages: role in pulmonary colonization. J. Exp. Med. 173(5), 1143-1149 (1991).
119. Guermonprez P, Khelef N, Blouin E et al. The adenylate cyclase toxin of Bordetella pertussis binds to target cells via the alpha(M)beta(2) integrin (CD11b/CD18). J. Exp. Med. 193(9), 1035-1044 (2001).
120. Lamberti Y, Gorgojo J, Massillo C, Rodriguez ME. Bordetella pertussis entry into respiratory epithelial cells and intracellular survival. Pathog. Dis. 69(3), 194-204 (2013).
121. Lamberti Y, Perez Vidakovics ML, Van Der Pol LW, Rodriguez ME. Cholesterolrich domains are involved in Bordetella pertussis phagocytosis and intracellular survival in neutrophils. Microb. Pathog. 44(6), 501-511 (2008).
122. Lamberti YA, Hayes JA, Perez Vidakovics ML, Harvill ET, Rodriguez ME. Intracellular trafficking of Bordetella pertussis in human macrophages. Infect. Immun. 78(3), 907-913 (2010).
123. Alonso S, Pethe K, Mielcarek N, Raze D, Locht C. Role of ADP-ribosyltransferase activity of pertussis toxin in toxin-adhesin redundancy with filamentous hemagglutinin during Bordetella pertussis infection. Infect. Immun. 69(10), 6038-6043 (2001).
124. Khelef N, Bachelet CM, Vargaftig BB, Guiso N. Characterization of murine lung inflammation after infection with parental Bordetella pertussis and mutants deficient in adhesins or toxins. Infect. Immun. 62(7), 2893-2900 (1994).
125. Warfel JM, Beren J, Kelly VK, Lee G, Merkel TJ. Nonhuman primate model of pertussis. Infect. Immun. 80(4), 1530-1536 (2012).
126. Warfel JM, Merkel TJ. Bordetella pertussis infection induces a mucosal IL-17 response and long-lived Th17 and Th1 immune memory cells in nonhuman primates. Mucosal Immunol. 6(4), 787-796 (2013).
127. Ishibashi Y, Nishikawa A. Bordetella pertussis infection of human respiratory epithelial cells up-regulates intercellular adhesion molecule-1 expression: role of filamentous hemagglutinin and pertussis toxin. Microb. Pathog. 33(3), 115-125 (2002).
128. Busby TF, Argraves WS, Brew SA, Pechik I, Gilliland GL, Ingham KC. Heparin binding by fibronectin module III-13 involves six discontinuous basic residues brought together to form a cationic cradle. J. Biol. Chem. 270(31), 18558-18562 (1995).
129. Cardin AD, Demeter DA, Weintraub HJ, Jackson RL. Molecular design and modeling of protein-heparin interactions. Methods Enzymol. 203, 556-583 (1991).
130. Lucena S, Arocha Pinango CL, Guerrero B. Fibronectin. Structure and functions associated to hemostasis. Invest. Clin. 48(2), 249-262 (2007).
131. Menozzi FD, Gantiez C, Locht C. Interaction of the Bordetella pertussis filamentous hemagglutinin with heparin. FEMS Microbiol. Lett. 62(1), 59-64 (1991).
132. Menozzi FD, Mutombo R, Renauld G et al. Heparin-inhibitable lectin activity of the filamentous hemagglutinin adhesin of Bordetella pertussis. Infect. Immun. 62(3), 769-778 (1994).
133. Ishibashi Y, Yoshimura K, Nishikawa A, Claus S, Laudanna C, Relman DA. Role of phosphatidylinositol 3-kinase in the binding of Bordetella pertussis to human monocytes. Cell Microbiol. 4(12), 825-833 (2002).
134. Rozdzinski E, Spellerberg B, Van Der Flier M et al. Peptide from a prokaryotic adhesin blocks leukocyte migration in vitro and in vivo. J. Infect. Dis. 172(3), 785-793 (1995).
135. Menozzi FD, Boucher PE, Riveau G, Gantiez C, Locht C. Surface-associated filamentous hemagglutinin induces autoagglutination of Bordetella pertussis. Infect. Immun. 62(10), 4261-4269 (1994).
136. Berggard K, Johnsson E, Mooi FR, Lindahl G. Bordetella pertussis binds the human complement regulator C4BP: role of filamentous hemagglutinin. Infect. Immun. 65(9), 3638-3643 (1997).
137. Berggard K, Lindahl G, Dahlback B, Blom AM. Bordetella pertussis binds to human C4b-binding protein (C4BP) at a site similar to that used by the natural ligand C4b. Eur. J. Immunol. 31(9), 2771-2780 (2001).
138. Fernandez RC, Weiss AA. Serum resistance in bvg-regulated mutants of Bordetella pertussis. FEMS Microbiol. Lett. 163(1), 57-63 (1998).
139. Berggard K, Johnsson E, Morfeldt E, Persson J, Stalhammar-Carlemalm M, Lindahl G. Binding of human C4BP to the hypervariable region of M protein: a molecular mechanism of phagocytosis resistance in Streptococcus pyogenes. Mol. Microbiol. 42(2), 539-551 (2001).
140. Carlsson F, Berggard K, Stalhammar-Carlemalm M, Lindahl G. Evasion of phagocytosis through cooperation between two ligand-binding regions in Streptococcus pyogenes M protein. J. Exp. Med. 198(7), 1057-1068 (2003).
141. Ishibashi Y, Nishikawa A. Role of nuclear factor-kappa B in the regulation of intercellular adhesion molecule 1 after infection of human bronchial epithelial cells by Bordetella pertussis. Microb. Pathog. 35(4), 169-177 (2003).
142. Bloemen PG, Van Den Tweel MC, Henricks PA et al. Stimulation of both human bronchial epithelium and neutrophils is needed for maximal interactive adhesion. Am. J. Physiol. 270(1 Pt 1), L80-L87 (1996).
143. O'Brien AD, Standiford TJ, Bucknell KA, Wilcoxen SE, Paine R 3rd. Role of alveolar epithelial cell intercellular adhesion molecule-1 in host defense against Klebsiella pneumoniae. Am. J. Physiol. 276(6 Pt 1), L961-L970 (1999).
144. Tosi MF, Stark JM, Smith CW, Hamedani A, Gruenert DC, Infeld MD. Induction of ICAM-1 expression on human airway epithelial cells by inflammatory cytokines: effects on neutrophil-epithelial cell adhesion. Am. J. Respir. Cell Mol. Biol. 7(2), 214-221 (1992).
145. Cuschieri J, Gourlay D, Garcia I, Jelacic S, Maier RV. Implications of proteasome inhibition: an enhanced macrophage phenotype. Cell Immunol. 227(2), 140-147 (2004).
146. Ward PA, Lentsch AB. Endogenous regulation of the acute inflammatory response. Mol. Cell. Biochem. 234-235(1-2), 225-228 (2002).
147. Jana NR, Dikshit P, Goswami A, Nukina N. Inhibition of proteasomal function by curcumin induces apoptosis through mitochondrial pathway. J. Biol. Chem. 279(12), 11680-11685 (2004).
148. D'cunha J, Knight E Jr, Haas AL, Truitt RL, Borden EC. Immunoregulatory properties of ISG15, an interferon-induced cytokine. Proc. Natl Acad. Sci. USA 93(1), 211-215 (1996).
149. D'cunha J, Ramanujam S, Wagner RJ, Witt PL, Knight E Jr, Borden EC. In vitro and in vivo secretion of human ISG15, an IFN-induced immunomodulatory cytokine. J. Immunol. 157(9), 4100-4108 (1996).
150. Giannakopoulos NV, Luo JK, Papov V et al. Proteomic identification of proteins conjugated to ISG15 in mouse and human cells. Biochem. Biophys. Res. 336(2), 496-506 (2005).
151. Recht M, Borden EC, Knight E Jr. A human 15-kDa IFN-induced protein induces the secretion of IFN-gamma. J. Immunol. 147(8), 2617-2623 (1991).
152. Decker T, Muller M, Stockinger S. The yin and yang of type I interferon activity in bacterial infection. Nat. Rev. Immunol. 5(9), 675-687 (2005).
153. Dirix V, Verscheure V, Goetghebuer T et al. Monocyte-derived interleukin-10 depresses the Bordetella pertussis-specific gamma interferon response in vaccinated infants. Clin. Vaccine Immunol. 16(12), 1816-1821 (2009).
154. Higgs R, Higgins SC, Ross PJ, Mills KH. Immunity to the respiratory pathogen Bordetella pertussis. Mucosal Immunol. 5(5), 485-500 (2012).
155. Goodwin MS, Weiss AA. Adenylate cyclase toxin is critical for colonization and pertussis toxin is critical for lethal infection by Bordetella pertussis in infant mice. Infect. Immun. 58(10), 3445-3447 (1990).
156. Roberts M, Cropley I, Chatfield S, Dougan G. Protection of mice against respiratory Bordetella pertussis infection by intranasal immunization with P.69 and FHA. Vaccine 11(8), 866-872 (1993).
157. Weiss AA, Goodwin MS. Lethal infection by Bordetella pertussis mutants in the infant mouse model. Infect. Immun. 57(12), 3757-3764 (1989).
158. Cotter PA, Yuk MH, Mattoo S et al. Filamentous hemagglutinin of Bordetella bronchiseptica is required for efficient establishment of tracheal colonization. Infect. Immun. 66(12), 5921-5929 (1998).
159. Mattoo S, Miller JF, Cotter PA. Role of Bordetella bronchiseptica fimbriae in tracheal colonization and development of a humoral immune response. Infect. Immun. 68(4), 2024-2033 (2000).
160. Poulain-Godefroy O, Menozzi FD, Alonso S et al. Adjuvant activity of free Bordetella pertussis filamentous haemagglutinin delivered by mucosal routes. Scand. J. Immunol. 58(5), 503-510 (2003).